Clinical Report: Synchronizing Time Zero and Treatment Assignment in Target Trial Emulation

Overview

This letter identifies potential temporal misalignment and time-varying confounding in a multicenter target trial emulation of left ventricular unloading during VA-ECMO for cardiogenic shock. The reported weighted 60-day mortality risk difference was 1.4% (95% CI, −11.8% to 14.6%); the authors of the letter state that this indicates no detectable association in the weighted overlap population, not equivalence between strategies.

Background

VA-ECMO is used as support for selected patients with cardiogenic shock, and left ventricular unloading may be considered when signs of LV distension or impaired aortic valve opening occur. The multicenter analysis by Dettling et al. compared unloading initiated within 24 hours of ECMO initiation with ECMO alone and used overlap weighting. The letter questions whether eligibility, treatment assignment, and follow-up were aligned at time zero, and whether evolving clinical indications for unloading were adequately addressed. It also notes that IABP and Impella use was closely associated with center, limiting separation of device and center effects.

Data Highlights

Key Findings

• If the 48-hour ECMO duration was an eligibility condition, it depended on post-baseline information and could exclude patients who died or were weaned earlier; the letter states that eligibility in a target trial emulation must be determinable at time zero.
• Classifying exposure by unloading received within 24 hours while starting follow-up at cannulation creates a grace-period concern: patients must survive until unloading to enter that exposure group, while earlier deaths cannot be classified in it.
• The letter describes cloning, artificial censoring, and inverse-probability-of-censoring weighting as methods to align strategies during a grace period; a 24-hour landmark analysis would apply only to patients alive and receiving support at that landmark.
• Reported unloading indications included pulmonary edema, LV dilation, elevated pulmonary artery occlusion pressure, very low aortic velocity-time integral, and continued failure of aortic valve opening. The letter notes that these evolving findings may predict unloading and mortality and may be affected by ECMO flow and inotropic therapy.
• Baseline propensity-score weighting cannot, according to the letter, address time-varying confounding from evolving indications; aortic velocity-time integral data were unavailable from one center, and unloading triggers were not standardized.
• Because IABP and Impella use were closely linked to center, the letter states that combining modalities prevents separation of device, center, and treatment-policy effects; the confidence interval also does not rule out clinically meaningful benefit or harm.

Clinical Implications

The letter calls for clarification of whether the 48-hour criterion was used and for reanalysis of the 24-hour grace period. It also proposes emulating clinically defined dynamic unloading strategies with time-updated hemodynamic and echocardiographic measurements; the reported estimate should be interpreted as an association in the weighted overlap population receiving local treatment practices, rather than evidence of equivalence.

Conclusion

The letter identifies eligibility timing, exposure assignment, evolving indications, and center-linked device use as limitations on causal interpretation of the neutral mortality finding. Clarifying eligibility and aligning treatment assignment with follow-up would strengthen interpretation of the comparison.

Related Resources & Content

1. Dettling et al., Critical Care, 2026 — Left ventricular unloading during VA-ECMO for refractory cardiogenic shock: a target trial emulation multicenter analysis
2. The BMJ, 2025 — Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
3. Journal of Clinical Epidemiology, 2025 — Review of methods to deal with the misalignment of times of eligibility, start of follow-up, and treatment assignment in studies explicitly aimed at emulating target trials
4. EARLY-UNLOAD trial, cited in the letter
5. ELSO, 2021 — Adult Cardiac VA-ECMO Guidelines
6. npj Digital Medicine — Accelerated Assessment of Left Ventricular Cardiac Activation Using Geometric Deep Learning: Advancing Planning for Cardiac Resynchronization Therapy
7. ASCO Publications — Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation
8. ASCO Publications — Beyond national benchmarks: An EMR-integrated platform for measuring local time to treatment infusion.
9. Frontiers in Cardiovascular Medicine — Individualized Interventricular Electrical Optimization Following Deep Septal Pacing in a Patient with Hypertrophic Cardiomyopathy and Preserved Ejection Fraction: A Case Study
10. Left ventricular unloading during VA-ECMO for refractory cardiogenic shock: a target trial emulation multicenter analysis
11. Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
12. Review of methods to deal with the misalignment of times of eligibility, start of follow-up, and treatment assignment in studies explicitly aimed at emulating target trials
13. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
14. Temporary mechanical circulatory support in cardiogenic shock
15. Adult Cardiac VA-ECMO Guidelines
16. 2026 ESC Guidelines for the management of heart failure | European Heart Journal | Oxford Academic
17. Impact of left ventricular unloading timing on clinical outcomes in venoarterial extracorporeal membrane oxygenation: an updated systematic review and meta-analysis | BMC Cardiovascular Disorders | Springer Nature Link
18. COMPARING OUTCOMES OF LV UNLOADING STRATEGIES IN PATIENTS ON VENO-ARTERIAL ECMO FOR CARDIOGENIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS - CHEST
19. Review of methods to deal with the misalignment of times of eligibility, start of follow-up, and treatment assignment in studies explicitly aimed at emulating target trials
20. Missing the target in target trial emulation | Critical Care | Springer Nature Link